An interventional study of VM-02 and Commercial Oral Probiotic Competitor in Vaginal Personal Care, sponsored by Seed Health. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-31.
Sponsored by Seed Health · Not applicable, Interventional, and Basic science
The goal of this clinical trial is to assess the impact of a personal care product on vaginal health in a healthy participant population. The personal care product, VM-02, contains a prebiotic, postbiotic, and three distinct strains of Lactobacillus crispatus, a microbe commonly found in healthy females, together accounting for greater than 85% of known genes in this species. The intervention will be compared to a placebo intervention and will aim to assess the following in a healthy female population:
Measure changes in the relative and absolute abundance of a bacterial species, Lactobacillus crispatus, in the vagina, compared the baseline (prior to use of the personal care product) to two time points after use.
Observe changes in vaginal pH and self-reported discomfort from vaginal odor, compared the baseline to two time points after use.
Determine the user experience of three variations of a personal care product administered in different formats to improve vaginal health and establish tolerability and user acceptability.
Participants will use the personal care product according to a specific program as directed, conduct vaginal swab sampling, and answer questionnaires, each at eight time points.
The vaginal microbiome is a dynamic microecosystem that undergoes fluctuations during the female menstrual cycle and at various life stages from puberty to menopause. A healthy vaginal microbiome is dominated by Lactobacillus which regulates vaginal pH, produces antimicrobial compounds, and significantly influences host immune response. The purpose of this study is to determine whether vaginal health can be influenced by a novel personal care product comprised of a Lactobacillus postbiotic, prebiotic, and multiple strains of Lactobacillus crispatus predictive of a stable vaginal microbiome.
This study will be a randomized double-blind, placebo-controlled intervention that will examine the safety and tolerability of a personal care product for vaginal health, VM-02. This pilot study will last for the duration of two complete menstrual cycles. Data will be collected via participant virtual questionnaires and vaginal swabs.
Participants are randomized as follows:
A two-arm randomized, double-blind, placebo-controlled study to evaluate VM-02 as a vaginal suppository capsule.
Arm #1: Vaginal application of single-use applicators filled with a vaginal suppository capsule at 5 x 10\^8 CFU/dose. The study product will be administered once daily for 7 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
Arm #2: Vaginal application of single-use applicators filled with a vaginal suppository placebo capsule. The study product will be administered once daily for 7 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
Three additional arms are included to quantify the impact of an alternative formulation and user experience.
Arm #3: Vaginal application of single-use applicators filled with vaginal suppository tablet at 5 x 10\^8 CFU/dose. The study product will be administered on Days 1,4,7,14,21.
Arm #4: Oral administration of capsule at 5 x 10\^8 cfu/dose. The study product will be administered daily for 30 consecutive days.
Arm #5: Oral administration of commercially available over-the-counter oral capsule at 5 x 10\^8 CFU/dose. The study product will be administered daily for 30 consecutive days.
Colonization rate of 3 distinct Lactobacillus crispatus after administration of VM-02 will be assessed with PCR and DNA sequence analysis.
Researchers will compare groups who received active product with those who received a placebo (a look-alike substance that contains no active drug) to determine product safety and any possible side effects, see if the amount of the bacterial species, Lactobacillus crispatus, changes (either increases or decreases) in response to the treatment, and to determine any impacts on self-reported odor and vaginal health.
A total of 80 participants will be recruited for this study. All participants will be supported and tracked through the various stages of the study virtually. All biomarker swabs that are taken by participants will be returned via pre-paid envelopes provided by the research team and all survey information will be collected online. No in-person visits will be required. Participants who are unwilling to follow the study protocol will be removed from the study.
Seed Health is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
In the VM-02 Vaginal Suppository Capsule Placebo Arm, participants will take the test vaginal suppository capsule placebo as directed.
Other: VM-02 Placebo
In the VM-02 Vaginal Suppository Capsule Active Arm, participants will take a test vaginal suppository capsule as directed.
Other: VM-02
In the VM-02 Vaginal Suppository Tablet Active Arm, participants will take a test vaginal suppository tablet as directed.
Other: VM-02
In the VM-02 Oral Capsule Active Arm, participants will take a test oral capsule as directed.
Other: VM-02
In the Commercial Over-The-Counter (OTC) Oral Probiotic Competitor Arm, participants will take an over-the-counter competitor product as directed.
Dietary Supplement: Commercial Oral Probiotic Competitor
VM-02 is a personal care product for vaginal health.
Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
VM-02 Placebo is a personal care product placebo for vaginal health.
Safety and tolerability of VM-02 at 5 x 10^8 CFU/dose based on frequency and absolute number of patient reported adverse events
Time frame: Throughout intervention and subsequent 4 week period following last dose
Vaginal colonization calculated by detection of each of 3 distinct Lactobacillus crispatus strains after administration of VM-02 at 5 x 10^8 CFU/dose using metagenomic sequencing and/or strain-specific PCR-based assays
Time frame: 2 and 4 weeks after intervention
Self-reported pH values after administration of VM-02 at 5 x 10^8 CFU/dose
Time frame: 2 and 4 weeks after intervention
Cytokine panel assays after administration of VM-02 at 5 x 10^8 CFU/dose
Time frame: 2 and 4 weeks after intervention
Participant self-reported questionnaire outcomes after administration of VM-02 at 5 x 10^8 CFU/dose
Time frame: 2 and 4 weeks after intervention
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seed Health